AX-2026-042239
Melanotan II · 10 mg declared · Hunan Aslsen Technology Co., Ltd. · lot HOMO-2511-M1199
MARGINALVERIFIED
- Report ID
- AX-2026-042239
- Compound
- Melanotan II
- Compound class
- Melanocortin-receptor peptides
- Supplier
- Homopeptide — Hunan Aslsen Technology Co., Ltd.
- Batch / lot
- HOMO-2511-M1199
- Declared label claim
- 10mg
- Laboratory
- VendorInvestigate
- Assay date
- 26 Feb 2026
- Submitted
- 10 Mar 2026
- Quarter
- 2026-Q1
- Submitter
- a.fontaine
- Sample provenance
- Buyer-sourced
Section 1
Results
Measured against the index acceptance specification for the melanocortin-receptor peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.
| Parameter | Method | Result | Unit | Index spec | |
|---|---|---|---|---|---|
| Purity | RP-HPLC, 32 min gradient, 214 nm | 99.03 | % area | ≥ 98.5 | PASS |
| Total impurities | RP-HPLC, sum of reported peaks | 0.97 | % area | ≤ 1.5 | PASS |
| Largest single impurity | RP-HPLC — linear (open-lactam) precursor (+18 Da) | 0.54 | % area | ≤ 1.00 | PASS |
| Identity — theoretical monoisotopic mass | calculated from molecular formula | 1023.5402 | Da | — | NOT TESTED |
| Identity — observed monoisotopic mass | LC-MS, high resolution (ESI-TOF/QTOF) | 1023.5444 | Da | — | NOT TESTED |
| Mass accuracy | observed vs theoretical | +4.1 | ppm | ± 15 | PASS |
| Total peptide content | by difference from the gravimetric mass balance | 91.68 | %w/w | — | NOT TESTED |
| Target-compound content | total peptide content × purity | 90.79 | %w/w | — | NOT TESTED |
| Gross fill (as weighed) | five-place balance, under nitrogen | 10.30 | mg | 10 mg declared | NOT TESTED |
| Recovered target peptide | gross fill × target content | 9.351 | mg | 10 mg claim | NOT TESTED |
| Recovery against label claim | recovered ÷ claim | 93.5 | % | 90.0 – 110.0 | PASS |
| Water content | Karl Fischer, coulometric, duplicate | 3.97 | % | ≤ 8.0 | PASS |
| Counter-ion (acetate) | anion-exchange ion chromatography | 4.20 | % | ≤ 10.0 | PASS |
| Residual solvent + inorganic residue | estimated — see /methods/residual-solvents-q3c/ | 0.15 | % | — | NOT TESTED |
| Endotoxin | kinetic chromogenic LAL | 0.31 | EU/mg | ≤ 5.0 | PASS |
| Sterility | membrane filtration, USP <71>, 14 d | No growth at 14 d | — | no growth | PASS |
| Appearance | visual, diffuse light, black and white background | White lyophilised cake, intact | — | white to off-white intact cake | PASS |
| Reconstitution clarity | reconstituted per submitter procedure | Clear, colourless, no visible particulates | — | clear, no visible particulates | PASS |
| pH (reconstituted, 1 mg/mL) | potentiometric, two-point calibration | 5.19 | — | 2.5 – 8.0 | PASS |
| Retention time (observed) | RP-HPLC, 32 min gradient | 10.46 | min | 10.44 ± 0.25 (normalised) | PASS |
| Peak asymmetry (10 % height) | Ph. Eur. 2.2.46 | 0.90 | — | 0.80 – 1.50 | PASS |
| Plate count, main peak | N = 5.54 (t/w½)² | 52,673 | — | ≥ 20,000 | PASS |
| Resolution to nearest impurity | vs [L-Phe7]-diastereomer | 0.91 | — | no index criterion | REPORTED |
Section 2
Chromatogram and peak integration
The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.
| # | Peak | RT | Area (µV·s) | % area | Δ mass (Da) |
|---|---|---|---|---|---|
| 1 | Melanotan II — main peak | 10.46 | 4,813,165 | 99.03 | — |
| 2 | linear (open-lactam) precursor (+18 Da) | 9.67 | 26,246 | 0.54 | +18.011 |
| 3 | [L-Phe7]-diastereomer | 10.29 | 9,235 | 0.19 | 0.000 |
| 4 | oxidised Trp (+16 Da) | 10.08 | 7,776 | 0.16 | +15.995 |
| 5 | MT-II dimer (head-to-tail) | 12.97 | 1,944 | 0.04 | +1023.540 |
| 6 | des-acetyl MT-II (−42 Da) | 9.95 | 1,944 | 0.04 | -42.011 |
| Closure check — purity + Σ impurities | 100.00 | CLOSES | |||
Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.
Section 3
Mass spectrum and identity
Theoretical monoisotopic mass 1023.5402 Da, computed from C50H69N15O9. All ppm figures on this site are against monoisotopic values — see why that matters.
| Charge | Theoretical m/z | Observed m/z | Δ m/z | Rel. abundance (%) |
|---|---|---|---|---|
| 3+ | 342.1873 | 342.1887 | 0.0014 | 8.6 |
| 2+ | 512.7774 | 512.7795 | 0.0021 | 57.9 |
| 1+ | 1024.5475 | 1024.5517 | 0.0042 | 100.0 |
Section 4
Gravimetric mass balance
Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.
| Component | Determination | %w/w of cake |
|---|---|---|
| Water | Karl Fischer | 3.97 |
| Counter-ion (acetate) | ion chromatography | 4.20 |
| Residual solvent + inorganic residue | estimated | 0.15 |
| Total peptide content | by difference | 91.68 |
| Total | 100.00 CLOSES | |
Supplier certificate, as declared
The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.
| Figure | Supplier COA | This report | Index note |
|---|---|---|---|
| Purity (% area) | 99.90 | 99.03 | divergence +0.84 pp vs batch median |
| Total impurities (% area) | not stated | 0.97 | |
| Largest single impurity (% area) | not stated | 0.54 | |
| Water (%) | not stated | 3.97 | |
| Counter-ion (%) | 5.4 | 4.20 | |
| Peptide content (%w/w) | 90.5 | 91.68 | |
| Endotoxin (EU/mg) | 0.16 | 0.31 | |
| Method stated on certificate | NO | — | no method section — the result cannot be reconciled against any other |
Section 5
Provenance and caveats
Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.
- Sample provenance
- Buyer-sourced
- Evidentiary weight
- Strongest available evidence in this index.
- Chain of custody
- Retail purchase → submitter (ambient, 27 d) → laboratory (hand-carried, 7 d) → assay.
- Assay date
- 26 Feb 2026
- Submitted to the index
- 10 Mar 2026
- Laboratory
- VendorInvestigate, Riga, Latvia
- Method basis
- 32 min gradient · high-resolution MS
- Verification status
- VERIFIED
Section 6
Annotations
No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.
Section 7
Related records
Same batch — lot HOMO-2511-M1199 n=12
| Report | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042240 | HOMO-2511-M1199 | Janoshik | 2026-Q1 | 99.31 | 4.42 | 99.4 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042241 | HOMO-2511-M1199 | Janoshik | 2026-Q1 | 99.64 | 3.64 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042242 | HOMO-2511-M1199 | VendorInvestigate | 2026-Q1 | 98.43 | 3.72 | — | Laboratory-retained | 1 | FAIL |
| AX-2026-042243 | HOMO-2511-M1199 | Janoshik | 2026-Q1 | 99.93 | 3.53 | 95.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042244 | HOMO-2511-M1199 | VendorInvestigate | 2026-Q1 | 98.69 | 3.82 | 106.5 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042245 | HOMO-2511-M1199 | VendorInvestigate | 2026-Q1 | 98.95 | 3.78 | 102.9 | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042246 | HOMO-2511-M1199 | Janoshik | 2026-Q1 | 99.05 | 3.83 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042247 | HOMO-2511-M1199 | PeptideMeter | 2026-Q1 | 99.01 | 3.34 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042248 | HOMO-2511-M1199 | PeptideMeter | 2026-Q1 | 99.39 | 3.96 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042249 | HOMO-2511-M1199 | PeptideMeter | 2026-Q1 | 99.93 | 3.66 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042250 | HOMO-2511-M1199 | Nordanalyt | 2026-Q1 | 99.06 | 4.02 | — | Laboratory-retained | 1 | MARGINAL |
Cross-sections
| Report | Supplier | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042648 | GGPeps | GGPE-2603-P8735 | Janoshik | 2026-Q3 | 99.10 | 6.97 | — | Supplier-supplied | 4 | MARGINAL |
| AX-2026-042479 | SWB | SWB-2603-A5707 | Janoshik | 2026-Q3 | 99.16 | 3.67 | 94.5 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042481 | SWB | SWB-2603-A5707 | Medutest | 2026-Q3 | 98.95 | 3.37 | 90.8 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042650 | GGPeps | GGPE-2603-P8735 | Medutest | 2026-Q3 | 99.86 | 6.49 | — | Supplier-supplied | 3 | MARGINAL |
| AX-2026-042483 | SWB | SWB-2603-A5707 | Janoshik | 2026-Q3 | 99.38 | 3.73 | 107.2 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042651 | GGPeps | GGPE-2603-P8735 | PeptideMeter | 2026-Q3 | 99.53 | 7.04 | 90.7 | Supplier-supplied | 4 | MARGINAL |
| AX-2026-042478 | SWB | SWB-2603-A5707 | VendorInvestigate | 2026-Q3 | 98.73 | 4.34 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042482 | SWB | SWB-2603-A5707 | Janoshik | 2026-Q3 | 99.22 | 4.66 | — | Supplier-supplied | 1 | MARGINAL |
| Report | Compound | Lot | Lab | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-042181 | Ipamorelin | HOMO-2608-A9045 | Janoshik | 2026-Q3 | 99.78 | 4.79 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042172 | Semaglutide | HOMO-2604-X8921 | Janoshik | 2026-Q3 | 99.64 | 5.16 | 91.9 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042278 | SLU-PP-332 | HOMO-2602-Y2822 | Kestrel | 2026-Q3 | 99.71 | 4.42 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042180 | Ipamorelin | HOMO-2608-A9045 | Janoshik | 2026-Q3 | 99.39 | 4.74 | 105.5 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042184 | Ipamorelin | HOMO-2608-A9045 | Kestrel | 2026-Q3 | 99.27 | 4.79 | 103.2 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042274 | SLU-PP-332 | HOMO-2602-Y2822 | VendorInvestigate | 2026-Q3 | 98.71 | 4.72 | — | Laboratory-retained | 0 | PASS |
| AX-2026-042183 | Ipamorelin | HOMO-2608-A9045 | VendorInvestigate | 2026-Q3 | 99.38 | 4.97 | — | Buyer-sourced | 1 | MARGINAL |
| AX-2026-042194 | Retatrutide | HOMO-2605-V9833 | PeptideMeter | 2026-Q3 | 98.90 | 4.07 | 98.8 | Supplier-supplied | 3 | MARGINAL |